NASDAQ:ORIC ORIC Pharmaceuticals (ORIC) Stock Price, News & Analysis $8.33 +0.12 (+1.46%) (As of 05:26 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About ORIC Pharmaceuticals Stock (NASDAQ:ORIC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ORIC Pharmaceuticals alerts:Sign Up Key Stats Today's Range$8.16▼$8.5650-Day Range$7.68▼$10.3052-Week Range$6.33▼$16.65Volume338,131 shsAverage Volume500,664 shsMarket Capitalization$587.82 millionP/E RatioN/ADividend YieldN/APrice Target$18.29Consensus RatingBuy Company OverviewORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More… ORIC Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks74th Percentile Overall ScoreORIC MarketRank™: ORIC Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 272nd out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageORIC Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about ORIC Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.84) to ($2.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -4.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 2.50. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.00% of the outstanding shares of ORIC Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 25.8, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently decreased by 1.48%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.16 Percentage of Shares Shorted16.00% of the outstanding shares of ORIC Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 25.8, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently decreased by 1.48%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.46 News SentimentORIC Pharmaceuticals has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for ORIC Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $350,749.00 in company stock.Percentage Held by InsidersOnly 5.55% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ORIC Pharmaceuticals' insider trading history. Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ORIC Stock News HeadlinesPratik S. Multani Sells 8,850 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) StockDecember 18, 2024 | insidertrades.comAnalysts Set ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) PT at $18.29December 23 at 3:49 AM | americanbankingnews.comHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.December 23, 2024 | Insiders Exposed (Ad)ORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesNovember 25, 2024 | globenewswire.comOric Pharmaceuticals Reports Strong Financial Growth and Clinical ProgressNovember 14, 2024 | markets.businessinsider.comOppenheimer Sticks to Its Buy Rating for Oric Pharmaceuticals (ORIC)November 13, 2024 | markets.businessinsider.comORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational UpdatesNovember 13, 2024 | markets.businessinsider.comPositive Outlook on ORIC-114: Promising Preclinical Results and Selective Efficacy Bolster Buy RatingNovember 5, 2024 | markets.businessinsider.comSee More Headlines ORIC Stock Analysis - Frequently Asked Questions How have ORIC shares performed this year? ORIC Pharmaceuticals' stock was trading at $9.20 at the beginning of the year. Since then, ORIC shares have decreased by 9.5% and is now trading at $8.33. View the best growth stocks for 2024 here. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.01. When did ORIC Pharmaceuticals IPO? ORIC Pharmaceuticals (ORIC) raised $75 million in an IPO on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO. Who are ORIC Pharmaceuticals' major shareholders? Top institutional investors of ORIC Pharmaceuticals include FMR LLC (6.21%), Alkeon Capital Management LLC (5.53%), State Street Corp (2.75%) and First Turn Management LLC (2.06%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli and Pratik S Multani. View institutional ownership trends. How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ORIC Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST). Company Calendar Last Earnings11/12/2024Today12/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORIC CUSIPN/A CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$18.29 High Stock Price Target$21.00 Low Stock Price Target$14.00 Potential Upside/Downside+119.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-42.47% Return on Assets-38.86% Debt Debt-to-Equity RatioN/A Current Ratio13.15 Quick Ratio13.15 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book2.50Miscellaneous Outstanding Shares70,567,000Free Float66,651,000Market Cap$588.53 million OptionableOptionable Beta1.13 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for January 2025. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ORIC) was last updated on 12/23/2024 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.